These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35566603)

  • 21. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
    Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
    Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study.
    Schmidt TP; Albanna W; Weiss M; Veldeman M; Conzen C; Nikoubashman O; Blume C; Kluger DS; Clusmann H; Loosen SH; Schubert GA
    Front Neurol; 2022; 13():841024. PubMed ID: 35359651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
    Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
    J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
    Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
    Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
    Özdirik B; Stueven A; Knorr J; Geisler L; Mohr R; Demir M; Hellberg T; Loosen SH; Benz F; Wiedenmann B; Tacke F; Wree A; Jann H; Roderburg C
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32486367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac and proinflammatory markers predict prognosis in cirrhosis.
    Wiese S; Mortensen C; Gøtze JP; Christensen E; Andersen O; Bendtsen F; Møller S
    Liver Int; 2014 Jul; 34(6):e19-30. PubMed ID: 24313898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of saliva and gingival crevicular fluid soluble urokinase plasminogen activator receptor (suPAR), galectin-1, and TNF-α levels in periodontal health and disease.
    Taşdemir İ; Erbak Yılmaz H; Narin F; Sağlam M
    J Periodontal Res; 2020 Oct; 55(5):622-630. PubMed ID: 32166745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Independent impact of periodontitis and cardiovascular disease on elevated soluble urokinase-type plasminogen activator receptor (suPAR) levels.
    Isola G; Polizzi A; Alibrandi A; Williams RC; Leonardi R
    J Periodontol; 2021 Jun; 92(6):896-906. PubMed ID: 33091149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
    Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
    Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy.
    Ivancsó I; Toldi G; Bohács A; Eszes N; Müller V; Rigó J; Vásárhelyi B; Losonczy G; Tamási L
    PLoS One; 2013; 8(4):e60697. PubMed ID: 23565268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
    Henriksen EK; Jørgensen KK; Kaveh F; Holm K; Hamm D; Olweus J; Melum E; Chung BK; Eide TJ; Lundin KE; Boberg KM; Karlsen TH; Hirschfield GM; Liaskou E
    J Hepatol; 2017 Jan; 66(1):116-122. PubMed ID: 27647428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparative Study of the Diagnostic and Prognostic Utility of Soluble Urokinase-type Plasminogen Activator Receptor and Procalcitonin in Patients with Sepsis and Systemic Inflammation Response Syndrome.
    Sharma A; Ray S; Mamidipalli R; Kakar A; Chugh P; Jain R; Ghalaut MS; Choudhury S
    Indian J Crit Care Med; 2020 Apr; 24(4):245-251. PubMed ID: 32565634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
    Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease.
    Hadley T; Gillespie S; Espinoza H; Prince J; Gronbaek H; Chandrakasan S; Kuguthasan S; Kolachala VL; Gupta NA
    Autoimmunity; 2020 Aug; 53(5):253-260. PubMed ID: 32370568
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in ankylosing spondylitis.
    Toldi G; Szalay B; Bekő G; Kovács L; Vásárhelyi B; Balog A
    Joint Bone Spine; 2013 Jan; 80(1):96-8. PubMed ID: 22999906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia.
    El-Mekkawy MS; Soliman SE; Saleh NY
    Turk J Pediatr; 2022; 64(1):98-109. PubMed ID: 35286036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential of volatile organic compounds to diagnose primary sclerosing cholangitis.
    van Vorstenbosch R; van Munster K; Stavropoulos G; Pachen D; van Schooten FJ; Ponsioen C; Smolinska A
    JHEP Rep; 2024 Aug; 6(8):101103. PubMed ID: 39131082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer.
    Rasmussen LJH; Schultz M; Iversen K; Eugen-Olsen J; Helms M; David K; Kjaer A; Lebech AM; Kronborg G
    Clin Biochem; 2020 Oct; 84():31-37. PubMed ID: 32504704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.